Planned for Chinon Vienne et Loire community in western France. First reactor would offer electricity generation, advanced research services, and medical isotope production. Land acquisition process initiated February 2025. Safety Options Dossier submitted to French Nuclear Safety and Radiation Protection Authority January 2026. Construction authorisation application expected by end of 2027. Commissioning target 2031. The reactor uses mixed uranium/plutonium oxide (MOX) fuel, with site acquisition and public consultation processes underway. Company-level context: Newcleo was founded in 2021, has raised over €645 million in total funding, employs approximately 1,000 people across France, Italy, the UK, Belgium, and Slovakia, and separately plans a larger commercial-scale 200 MWe LFR design (a distinct project from this 30 MWe demonstrator).